Type 1 Diabetes Efficacy Studies

In Vivo Pharmacology Services at JAX performs efficacy studies using the spontaneous NOD/ShiLtJ (001976) and STZ-inducible Type 1 Diabetes mouse models.

Request a quote

Type 1 diabetes (T1D), also called insulin-dependent diabetes mellitus (IDDM), is characterized by the autoimmune destruction of pancreatic beta cells. As a result, patients produce inadequate amounts of insulin. In Vivo Pharmacology Services at JAX performs efficacy studies using the spontaneous NOD/ShiLtJ (001976) and STZ-inducible Type 1 Diabetes mouse models.

Phenotype STZ Models C57BL/6J (JR# 000664) Inducible NOD/ShiLtJ (JR# 001976) Spontaneous Method
Blood Glucose Glucometer
Urine Glucose Diastix
Serum Insulin ELISA
Insulitis x H&E Staining
Pancreatic Lymph Node Phenotyping x Flow Cytometry
Serum Cytokines x Meso Scale Discovery
Pancreatic Islet Phenotyping qPCR/Simple Wes
Pancreatic B-Cell Apoptosis TUNEL IHC
Diabetic Retinopathy x Retinal Flat Mount Staining and Microscopy
Diabetic Nephropathy x Urine ACR/Kidney Pathology

Example Efficacy Study Using STZ-Inducible Model:

  • Male C57BL/6J mice, 6-8 weeks of age
  • Clinical parameters such as blood and urine glucose collected weekly
  • Prophylactic (prior to detection of elevated glucose) or therapeutic (after detection of elevated glucose) dosing
  • Histochemical analysis of pancreatic islet cells

Experimental Timelines:

Representative Data:

Figure 1. STZ induces Type 1 Diabetes in C57BL/6J male mice. STZ-treated mice (n=8) exhibited higher blood glucose levels compared with vehicle-treated mice (n=4). *p<0.05; **p<0.01.

Figure 2. Oral glucose tolerance test and serum insulin assessment in STZ-induced Type 1 Diabetes mice. On study day 21, blood glucose levels were determined prior (T0) and after 15, 30, 60 and 120 min post-glucose administration in STZ-induced Type 1 Diabetes and non-diabetic control mice. STZ-treated mice exhibited higher blood glucose levels compared to vehicle-treated mice. ** p<0.01. Sera insulin was determined at 0 and 5 min post glucose administration. STZ-treated mice exhibited lower serum insulin values compared to vehicle- treated mice.


 

Example Efficacy Study Using NOD/ShiLtJ Model:

  • Female NOD/ShiLtJ (001976) mice, 6-8 weeks of age
  • Clinical parameters such as blood and urine glucose collected weekly
  • Prophylactic (prior to detection of elevated glucose) or therapeutic (after detection of elevated glucose) dosing
  • Histochemical analysis of pancreatic islet cells

Experimental Timeline


Representative Data:

Figure 4. Diabetes Incidence. DIDS treatment decreases blood glucose levels and delays the onset of diabetes.

Figure 5. Blood Glucose. anti-CD3 treatment in NOD/ShiLtJ diabetic mice decreases blood glucose levels.